Global Bevacizumab Biosimilar Market

Report ID : 1073 | Published : 2021-07-23 | Pages: 140 | Format: PDF/EXCEL

Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A) biologic activity (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic therapy approved for the treatment of human cancer. The drug was developed by F. Hoffmann-La Roche AG and approved by US FDA in February 2004 as first-line therapy in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer. Bevacizumab is approved for the treatment of patients with cervical, epithelial ovarian, and fallopian tube cancer in the United States and Europe. Bevacizumab is also approved for the treatment of patients with non-small-cell lung cancer and metastatic renal cell carcinoma. Also, it is indicated for the treatment of patients with glioblastoma in the United States and use in metastatic breast cancer in Europe. Bevacizumab is approved by European Medicines Agency in 2005 and marketed under the trade name Avastin.

Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. Due to the high cost of the biologics, significant companies are focused on the development of biosimilar to fulfill the need of low-income patients as well as expand their coverage. Patent of avastin will expire in Europe in 2022, and in the U.S., the patent will expire in 2019. Thus many biosimilar of bevacizumab is in development phase and are expected to come into the market in the forecast period. Introduction to biosimilars, increase in incidence and prevalence rate of various cancer, rising demand for targeted therapy, and price cuts have boosted the growth of bevcizumab biosimilar market. However, the stringent regulatory process for the approval of bevacizumab biosimilar, intense competition, and disappointing pipeline results are the major restraining factors for the growth of the bevacizumab biosimilar market.
Based on application, the global bevacizumab biosimilar market is segmented in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Non-Small Cell Lung Cancer and Colorectal Cancer segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate. Based on distribution channel the global bevacizumab biosimilar market is segmented as hospital pharmacy, online pharmacy and others. Hospital pharmacy segment is expected to grow during forecast period due to increase in number of hospital visit and hospital stays.
At regional level, the global bevacizumab biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global bevacizumanb biosimilar market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Early availability of biosimilar and emerging and huge population base countries such as China and India offers tremendous market opportunities for the bevacizumab biosimilar market.
Some of the market players leading the global bevacizumab biosimilar market include Hetero, Amgen, Biocon, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and among others.

  • Amgen
  • AryoGen Pharmed
  • Biothera
  • Boehringer Ingelheim
  • Centus Biotherapeutics
  • Henlius Biotech
  • Innovent Biologics
  • Mylan
  • mAbxience
  • Outlook Therapeutics
  • Pfizer
  • Prestige Biopharma
  • Roche
  • Samsung Bio
  • TOT Biopharm

Global Bevacizumab Biosimilar Market Segmentation

Global Bevacizumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Product

  • Avastin
  • Mvasi
  • Zirabev
  • Aybintio
  • Other Clinical Trial Products

Global Bevacizumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Application

  • Colorectal cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Renal cell carcinoma
  • Cervical cancer
  • Ovarian cancer

Global Bevacizumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

Global Bevacizumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients